| Target Price | $60.96 |
| Price | $25.44 |
| Potential |
139.60%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Zepp Health ADR A ADR 2026 .
The average Zepp Health ADR A ADR target price is $60.96.
This is
139.60%
register free of charge
$63.24
148.59%
register free of charge
$59.88
135.39%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Zepp Health ADR A ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Zepp Health ADR A ADR stock has an average upside potential 2026 of
139.60%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 182.60 | 1,808.00 |
| 48.25% | 890.14% | |
| EBITDA Margin | -23.13% | -8.92% |
| 258.55% | 61.43% | |
| Net Margin | -41.47% | -11.32% |
| 371.77% | 72.71% |
4 Analysts have issued a sales forecast Zepp Health ADR A ADR 2025 . The average Zepp Health ADR A ADR sales estimate is
This results in the following potential growth metrics:
3 Zepp Health ADR A ADR Analysts have issued a net profit forecast 2025. The average Zepp Health ADR A ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.29 | -0.88 |
| 123.08% | 203.45% | |
| P/E | negative | |
| EV/Sales | 0.30 |
3 Analysts have issued a Zepp Health ADR A ADR forecast for earnings per share. The average Zepp Health ADR A ADR EPS is
This results in the following potential growth metrics and future valuations:
Zepp Health ADR A ADR...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


